- Home
- ATIF vs MIRA Comparison
ATIF vs MIRA Comparison
Compare ATIF & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATIF
- MIRA
- Stock Information
- Founded
- ATIF 2015
- MIRA 2020
- Country
- ATIF United States
- MIRA United States
- Employees
- ATIF N/A
- MIRA N/A
- Industry
- ATIF Professional Services
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- ATIF Consumer Discretionary
- MIRA Health Care
- Exchange
- ATIF Nasdaq
- MIRA Nasdaq
- Market Cap
- ATIF 9.8M
- MIRA 17.1M
- IPO Year
- ATIF 2019
- MIRA 2023
- Fundamental
- Price
- ATIF $0.86
- MIRA $1.05
- Analyst Decision
- ATIF
- MIRA Strong Buy
- Analyst Count
- ATIF 0
- MIRA 2
- Target Price
- ATIF N/A
- MIRA $14.00
- AVG Volume (30 Days)
- ATIF 214.7K
- MIRA 538.5K
- Earning Date
- ATIF 12-13-2024
- MIRA 11-11-2024
- Dividend Yield
- ATIF N/A
- MIRA N/A
- EPS Growth
- ATIF N/A
- MIRA N/A
- EPS
- ATIF N/A
- MIRA N/A
- Revenue
- ATIF $500,000.00
- MIRA N/A
- Revenue This Year
- ATIF N/A
- MIRA N/A
- Revenue Next Year
- ATIF N/A
- MIRA N/A
- P/E Ratio
- ATIF N/A
- MIRA N/A
- Revenue Growth
- ATIF N/A
- MIRA N/A
- 52 Week Low
- ATIF $0.58
- MIRA $0.51
- 52 Week High
- ATIF $1.50
- MIRA $6.40
- Technical
- Relative Strength Index (RSI)
- ATIF 46.75
- MIRA 38.49
- Support Level
- ATIF $0.85
- MIRA $1.05
- Resistance Level
- ATIF $1.50
- MIRA $1.12
- Average True Range (ATR)
- ATIF 0.18
- MIRA 0.07
- MACD
- ATIF -0.01
- MIRA 0.02
- Stochastic Oscillator
- ATIF 15.82
- MIRA 12.00
About ATIF ATIF Holdings Limited
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.